Results 21 to 30 of about 110,621 (200)
Development of [124/125I]IAZA as a New Proteinopathy Imaging Agent for Alzheimer’s Disease
Molecules, 2023 Radioiodinated imaging agents for Aβ amyloid plaque imaging in Alzheimer’s disease (AD) patients have not been actively pursued. Our previous studies employed the “diaza” derivatives [11C]TAZA and [18F]flotaza in order to develop successful positron ...
Thrisha T. Reddy +5 more
doaj +1 more source
Research Progress of PET Traces for Alzheimer’s Disease
Journal of Isotopes, 2014 Alzheimer’s disease (AD) is unknown cause progressive degenerative diseases of central nervous system. It is a serious threat to the health of the elderly people. The diagnosis is mainly based on pathological examination after death.
TANG Cai-hua1，2;HU Kong-zhen1;TANG Gang-hua1
doaj +1 more source
Frontiers in Neuroscience, 2022 The development of novel PET imaging agents for synaptic vesicle glycoprotein 2A (SV2A) allowed for the in vivo detection of synaptic density changes, which are correlated with the progression and severity of a variety of neuropsychiatric diseases. While
Takuya Toyonaga +6 more
doaj +1 more source
Noninvasive molecular imaging of neuroinflammation [PDF]
, 2011 Inflammation is a highly dynamic and complex adaptive process to preserve and restore tissue homeostasis. Originally viewed as an immune-privileged organ, the central nervous system (CNS) is now recognized to have a constant interplay with the innate and
Jacobs, A.H. (Andreas) +13 more
core +1 more source
EJNMMI Research, 2020 Background Mesenchymal stem cells (MSCs) have shown potential for treatment of different diseases. However, their working mechanism is still unknown. To elucidate this, the non-invasive and longitudinal tracking of MSCs would be beneficial.
Sarah Belderbos +10 more
doaj +1 more source
τBu₂SiF-Derivatized D₂-Receptor Ligands: The First SiFA-Containing Small Molecule Radiotracers for Target-Specific PET-Imaging [PDF]
, 2011 The synthesis, radiolabeling and in vitro evaluation of new silicon-fluoride acceptor (SiFA) derivatized D-2-receptor ligands is reported. The SiFA-technology simplifies the introduction of fluorine-18 into target specific biomolecules for Positron ...
Wängler, Carmen +21 more
core +1 more source
Journal of Integrative Neuroscience, 2023 Computed tomography (CT) and magnetic resonance imaging (MRI) provide key structural information on brain pathophysiology. Positron emission tomography (PET) measures metabolism in the living brain; it plays an important role in molecular neuroimaging ...
Ferdinando Calabria +5 more
doaj +1 more source
Prostate Cancer-Specific Positron Emission Tomography with Different Radiotracers. [PDF]
Egyptian Journal of Nuclear Medicine, 2020 Imaging evaluation of prostate cancer needs to be tailored for various radiopharmaceuticals being remarkably heterogeneous disease. Positron emission tomography (PET) has played a relatively limited role in prostate cancer imaging.
Alshemeili, M.
doaj +1 more source
Development of Novel Fluorine-18 Labeled PET Radioligands for Monoamine Oxidase B (MAO-B) [PDF]
, 2013 Monoamine oxidases (MAO-A and MAO-B) are important enzymes regulating the levels of monoaminergic neurotransmitters. Selective and irreversible MAO-B inhibitors such as L-deprenyl and rasagiline are clinically used for the treatment of psychiatric and ...
Nag, Sangram
core +1 more source
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer [PDF]
Journal of Clinical Investigation, 2018 Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad population of patients with ovarian cancer; however, resistance caused by low enzyme expression of the drug target PARP-1 remains to be clinically evaluated in this context. We hypothesize that PARP-1 expression is variable in ovarian cancer and can be quantified in primary and ...
Mehran Makvandi +17 more
openaire +2 more sources